中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(11): 2278-2285

A cohort study on cumulative atherogenic index of plasma for predicting the risk of developing new-onset non-alcoholic fatty liver disease in a population of young and middle-aged individuals

DOI: 10.12449/JCH251113
  • 1.

    Department of Catheterization，Tangshan Workers’Hospital，Tangshan，Hebei 063000，China

  • 2.

    Department of Cardiology，Tangshan Workers’Hospital，Tangshan，Hebei 063000，China

  • 3.

    School of Clinical Medicine，Hebei Medical University，Shijiazhuang 050017，China

  • 4.

    School of Clinical Medicine，Nankai University，Tianjin 300071，China

  • 5.

    Department of Cardiology，Kailuan General Hospital，Tangshan，Hebei 063000，China

  • 6.

    School of Clinical Medicine，North China University of Science and Technology，Tangshan，Hebei 063000，China

Research funding:

Hebei Provincial Medical Science Research Project (20231775)

More Information
  • Corresponding author: HAN Quanle， hanquanle@126.com （ORCID： 0000-0002-3200-9224）
  • Received Date: 2025-01-02
  • Accepted Date: 2025-02-24
  • Published Date: 2025-11-25
    Abstract
  •   Objective  To investigate the association between cumulative atherogenic index of plasma （cumAIP） and the risk of new-onset nonalcoholic fatty liver disease （NAFLD） in young and middle-aged individuals.  Methods  A prospective cohort study was conducted among the young and middle-aged individuals （aged 18 to <60 years） in the Kailuan study cohort who underwent physical examination in Kailuan General Hospital and its 10 affiliated hospitals in June 2006 to October 2010， and after screening based on the inclusion and exclusion criteria， 33 987 individuals were included in the observation cohort. The individuals were divided into Q1， Q2， Q3， and Q4 groups based on the quantiles of cumAIP. The Kaplan-Meier method was used to calculate the cumulative incidence rate of new-onset NAFLD in the four groups， while the log-rank test was used for comparison between groups. A multivariate Cox regression analysis was used to obtain the hazard ratio （HR） and 95% confidence interval （CI） of the risk of new-onset NAFLD in the four groups. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups， and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups； the chi-square test was used for comparison of categorical variables between groups.  Results  The mean follow-up was 10.89±2.54 years， and there were 6 011 cases of new-onset NAFLD， including 995 cases in the Q1 group， 1 366 in the Q2 group， 1661 in the Q3 group， and 1 989 in the Q4 group， with an incidence density of 11.37， 16.02， 19.97， and 24.91 per thousand person-years. The log-rank test showed that there was a significant difference in cumulative incidence rate between the four groups （P<0.001）. With the presence or absence of NAFLD as the dependent variable and the quantiles of different exposure levels to cumAIP as the independent variable， the multivariate Cox regression model analysis showed that compared with the Q1 group， the Q2， Q3， and Q4 groups had an HR of 1.30 （95%CI： 1.20 — 1.41）， 1.52 （95%CI： 1.41 — 1.65）， and 1.79 （95%CI： 1.64 — 1.95）， respectively， for new-onset NAFLD， with a Ptrend value of <0.001. With the presence or absence of new-onset NAFLD as the dependent variable and the cumulative exposure to AIP for 0， 2， 4， and 6 years as the independent variable， the Cox regression analysis showed that compared with cumulative exposure to AIP for 0 years， cumulative exposure to AIP for 2， 4， and 6 years had an HR of 1.24 （95%CI： 1.15 — 1.35）， 1.51 （95%CI： 1.40 — 1.64）， and 1.70 （95%CI： 1.56 — 1.84）， respectively， with a Ptrend value of <0.001. A sensitivity analysis was performed after exclusion of the individuals with new-onset NAFLD within 2 years， the individuals who experienced atherosclerotic cardiovascular disease events during follow-up， and the individuals taking antihypertensive， hypoglycemic， and lipid-lowering drugs， and the results were similar to those of the main analysis. Considering the competitive relationship between all-cause death and outcome events， a competing risk analysis of death was performed， which showed that the results of risk analysis were similar to those of the main analysis.  Conclusion  A high level of cumAIP exposure can increase the risk of new-onset NAFLD in young and middle-aged individuals.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and Meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
    [2]
    YIP TC, LEE HW, CHAN WK, et al. Asian perspective on NAFLD-associated HCC[J]. J Hepatol, 2022, 76( 3): 726- 734. DOI: 10.1016/j.jhep.2021.09.024.
    [3]
    ZHOU ZF, LI Y, HUANG SQ, et al. Study on the relationship between serum uric acid and non-alcoholic fatty liver disease in physical examination population aged 18 to 60 years in Luzhou city[J]. Mod Prev Med, 2023, 50( 9): 1722- 1728. DOI: 10.20043/j.cnki.MPM.202301105.

    周仲芳, 李洋, 黄素琼, 等. 泸州市18～60岁体检人群血尿酸水平与非酒精性脂肪肝关系研究[J]. 现代预防医学, 2023, 50( 9): 1722- 1728. DOI: 10.20043/j.cnki.MPM.202301105.
    [4]
    ZHANG YX, WANG Y, YOU CL, et al. Analysis of factors related to abnormal liver function in patients with non alcoholic fatty liver disease[J]. Clin J Med Offic, 2025, 53( 5): 522- 524, 528. DOI: 10.16680/j.1671-3826.2025.05.21.

    张月霞, 王宇, 尤丛蕾, 等. 非酒精性脂肪肝患者肝功能异常相关因素分析[J]. 临床军医杂志, 2025, 53( 5): 522- 524, 528. DOI: 10.16680/j.1671-3826.2025.05.21.
    [5]
    CHEN ZB, HUANG LY, WANG BY, et al. Research advances in the association between metabolic associated fatty liver and type 2 diabetes mellitus and the mechanism of comorbidity[J]. J Clin Hepatol, 2023, 39( 10): 2454- 2459. DOI: 10.3969/j.issn.1001-5256.2023.10.025.

    陈兆斌, 黄丽媛, 王炳元, 等. 代谢相关脂肪性肝病与2型糖尿病的关系及共病机制研究进展[J]. 临床肝胆病杂志, 2023, 39( 10): 2454- 2459. DOI: 10.3969/j.issn.1001-5256.2023.10.025.
    [6]
    OU FB, LUO SH, LI XF, et al. Metabolic-associated fatty liver disease as a driver of chronic kidney disease[J]. J Clin Exp Med, 2023, 22( 4): 443- 447. DOI: 10.3969/j.issn.1671-4695.2023.04.030.

    欧芳波, 罗沈晖, 李学锋, 等. 代谢相关脂肪性肝病:慢性肾脏病的一个启动因素[J]. 临床和实验医学杂志, 2023, 22( 4): 443- 447. DOI: 10.3969/j.issn.1671-4695.2023.04.030.
    [7]
    GAO LL, WANG Y, YAN HF, et al. Characteristics of cardiometabolic risk in patients with different subtypes of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2025, 41( 1): 63- 68. DOI: 10.12449/JCH250110.

    高黎黎, 王勇, 严华芳, 等. 不同亚型非酒精性脂肪性肝病患者代谢性心血管病风险因素的特征分析[J]. 临床肝胆病杂志, 2025, 41( 1): 63- 68. DOI: 10.12449/JCH250110.
    [8]
    LI X, CHEN Y, LIU X, et al. Differences in the diagnosis and treatment guidelines at home and abroad for non-alcoholic fatty liver disease and treatment prospects[J]. Chin J Arterioscler, 2024, 32( 4): 347- 354. DOI: 10.20039/j.cnki.1007-3949.2024.04.010.

    黎翔, 陈弋, 刘霞, 等. 非酒精性脂肪性肝病国内外诊疗指南的区别及治疗展望[J]. 中国动脉硬化杂志, 2024, 32( 4): 347- 354. DOI: 10.20039/j.cnki.1007-3949.2024.04.010.
    [9]
    KAN YL, LI YM, TANG MH, et al. A prospective cohort study on the association between blood lipid levels and the risk of non-alcoholic fatty liver disease in a community population[J]. Chin Prev Med, 2024, 25( 5): 519- 525. DOI: 10.16506/j.1009-6639.2024.05.002.

    阚云龙, 李咏梅, 唐敏华, 等. 社区人群血脂水平与非酒精性脂肪肝病发病风险队列研究[J]. 中国预防医学杂志, 2024, 25( 5): 519- 525. DOI: 10.16506/j.1009-6639.2024.05.002.
    [10]
    DOBIÁS̆OVÁ M, FROHLICH J. The plasma parameter log(TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma(FERHDL)[J]. Clin Biochem, 2001, 34( 7): 583- 588. DOI: 10.1016/S0009-9120(01)00263-6.
    [11]
    ISMAIEL A, CIOBANU OS, ISMAIEL M, et al. Atherogenic index of plasma in non-alcoholic fatty liver disease: Systematic review and meta-analysis[J]. Biomedicines, 2022, 10( 9): 2101. DOI: 10.3390/biomedicines10092101.
    [12]
    YUAN Y, SHI J, SUN W, et al. The positive association between the atherogenic index of plasma and the risk of new-onset hypertension: A nationwide cohort study in China[J]. Clin Exp Hypertens, 2024, 46( 1): 2303999. DOI: 10.1080/10641963.2024.2303999.
    [13]
    ZHANG W, XIE WC, XU JE. Cross-sectional study of relationship between the Atherogenic Index of Plasma(AIP) and the risk of diabetes[J]. Mod Prev Med, 2018, 45( 14): 2676- 2679.

    张文, 解为慈, 徐金娥. 血浆致动脉硬化指数(AIP)与糖尿病关系的横断面研究[J]. 现代预防医学, 2018, 45( 14): 2676- 2679.
    [14]
    FERNÁNDEZ-MACÍAS JC, OCHOA-MARTÍNEZ AC, VARELA-SILVA JA, et al. Atherogenic index of plasma: Novel predictive biomarker for cardiovascular illnesses[J]. Arch Med Res, 2019, 50( 5): 285- 294. DOI: 10.1016/j.arcmed.2019.08.009.
    [15]
    YUAN Y, HU JW, WANG Y, et al. Association between atherogenic index of plasma and subclinical renal damage over a 12-year follow-up: Hanzhong adolescent hypertension study[J]. Eur J Clin Nutr, 2020, 74( 2): 278- 284. DOI: 10.1038/s41430-019-0530-x.
    [16]
    LIU SH, LIU Q, HAN X, et al. Association of trajectories of atherogenic index of plasma with atherosclerotic cardiovascular disease[J]. Chin Circ J, 2024, 39( 7): 676- 681. DOI: 10.3969/j.issn.1000-3614.2024.07.004.

    刘士贺, 刘倩, 韩旭, 等. 血浆致动脉粥样硬化指数轨迹与动脉粥样硬化性心血管疾病的关联[J]. 中国循环杂志, 2024, 39( 7): 676- 681. DOI: 10.3969/j.issn.1000-3614.2024.07.004.
    [17]
    HOU QQ, QI Q, HAN QL, et al. Association of the triglyceride-glucose index with early-onset atherosclerotic cardiovascular disease events and all-cause mortality: A prospective cohort study[J]. Cardiovasc Diabetol, 2024, 23( 1): 149. DOI: 10.1186/s12933-024-02249-4.
    [18]
    ZHANG YJ, CHEN SH, TIAN X, et al. Association between cumulative atherogenic index of plasma exposure and risk of myocardial infarction in the general population[J]. Cardiovasc Diabetol, 2023, 22( 1): 210. DOI: 10.1186/s12933-023-01936-y.
    [19]
    Fatty Liver and Alcoholic Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for management of nonalcoholic fatty liver disease: An updated and revised edition[J]. Chin J Gastroenterol Hepatol, 2010, 19( 6): 483- 487. DOI: 10.3969/j.issn.1006-5709.2010.06.001.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 胃肠病学和肝病学杂志, 2010, 19( 6): 483- 487. DOI: 10.3969/j.issn.1006-5709.2010.06.001.
    [20]
    Revision Committee of Chinese Guidelines for the Prevention and Treatment of Hypertension, Hypertension Alliance(China); Chinese Society of Cardiology of the Chinese Medical Association; Hypertension Committee of the Chinese Medical Doctor Association, et al. 2018 Chinese guidelines for the management of hypertension[J]. Chin J Cardiovasc Med, 2019, 24( 1): 24- 56. DOI: 10.3969/j.issn.1009-816X.2019.01.001.

    中国高血压防治指南修订委员会高血压联盟中国, 中华医学会心血管病学分会, 中国医师协会高血压专业委员会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24( 1): 24- 56. DOI: 10.3969/j.issn.1009-816X.2019.01.001.
    [21]
    Chinese Diabetes Society, Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China(2020 edition)[J]. Chin J Diabetes Mellit, 2021, 13( 4): 315- 409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13( 4): 315- 409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
    [22]
    Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management(2023)[J]. Chin Circ J, 2023, 38( 3): 237- 271. DOI: 10.3969/j.issn.1000-3614.2023.03.001.

    中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38( 3): 237- 271. DOI: 10.3969/j.issn.1000-3614.2023.03.001.
    [23]
    QIAO X, HU YQ, FAN YZ, et al. Associations between obesity and non-alcoholic fatty liver disease and the mediating role of hyperuricemia in the occupational population[J]. Mod Prev Med, 2024, 51( 4): 607- 612. DOI: 10.20043/j.cnki.MPM.202312222.

    乔栩, 胡玉麒, 范云喆, 等. 职业人群肥胖与非酒精性脂肪肝关联及高尿酸血症的中介作用分析[J]. 现代预防医学, 2024, 51( 4): 607- 612. DOI: 10.20043/j.cnki.MPM.202312222.
    [24]
    WANG Q, ZHENG DM, LIU J, et al. Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: A cross-sectional study[J]. Lipds Health Dis, 2018, 17( 1): 284. DOI: 10.1186/s12944-018-0932-0.
    [25]
    AMARAPURKAR D, KAMANI P, PATEL N, et al. Prevalence of non-alcoholic fatty liver disease: Population based study[J]. Ann Hepatol, 2007, 6( 3): 161- 163. DOI: 10.1016/S1665-2681(19)31922-2.
    [26]
    LI KM, LI J, CHENG XY, et al. Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants[J]. Front Endocrinol, 2022, 13: 969783. DOI: 10.3389/fendo.2022.969783.
    [27]
    PENG HW, ZHANG JC, HUANG XH, et al. Development and validation of an online dynamic nomogram based on the atherogenic index of plasma to screen nonalcoholic fatty liver disease[J]. Lipids Health Dis, 2023, 22: 44. DOI: 10.1186/s12944-023-01808-0.
    [28]
    WANG LL, YI JY, GUO XL, et al. Associations between life’s essential 8 and non-alcoholic fatty liver disease among US adults[J]. J Transl Med, 2022, 20( 1): 616. DOI: 10.1186/s12967-022-03839-0.
    [29]
    ZHANG XL, ZHENG QR, WANG QS, et al. Summary of the best evidence of exercise management for patients with nonalcoholic fatty liver disease[J]. Chin J Nurs, 2023, 58( 20): 2464- 2471. DOI: 10.3761/j.issn.0254-1769.2023.20.005.

    张雪玲, 郑奇容, 王巧松, 等. 非酒精性脂肪肝患者运动管理的最佳证据总结[J]. 中华护理杂志, 2023, 58( 20): 2464- 2471. DOI: 10.3761/j.issn.0254-1769.2023.20.005.
    [30]
    ZHU XR, LI X, ZHAO X, et al. Association between dietary patterns and non-alcoholic fatty liver disease in Chengdu[J]. Mod Prev Med, 2023, 50( 9): 1589- 1593, 1598. DOI: 10.20043/j.cnki.MPM.202212337.

    朱兴任, 李选, 赵星, 等. 成都地区膳食模式与非酒精性脂肪肝的关联性研究[J]. 现代预防医学, 2023, 50( 9): 1589- 1593, 1598. DOI: 10.20043/j.cnki.MPM.202212337.
    [31]
    YANG R, WANG L. Influence of lifestyle habits on nonalcoholic fatty liver disease[J]. Sci Sin Vitae, 2024, 54( 5): 819- 830. DOI: 10.1360/SSV-2024-0023.

    杨睿, 王琳. 生活习惯对非酒精性脂肪肝病的影响[J]. 中国科学: 生命科学, 2024, 54( 5): 819- 830. DOI: 10.1360/SSV-2024-0023.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3) PDF downloads(3) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return